Lipocine announces financial results for the full year ended december 31, 2023

Salt lake city , march 7, 2024 /prnewswire/ -- lipocine inc. (nasdaq: lpcn), a biopharmaceutical company focused on treating central nervous system ("cns") disorders, today announced financial results for the year ended december 31, 2023 and provided a corporate update. neuroactive steroids lipocine announced positive topline results from a pharmacokinetics ("pk") pilot bridge study of lpcn 1154 (oral brexanolone).
LPCN Ratings Summary
LPCN Quant Ranking